The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Complementary role of Ki67 index and 70-gene signature (MammaPrint) high-risk patients in the St Gallen risk group with uncertain chemotherapy suggestion.
Paolo Pronzato
Honoraria - Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag
Giorgio Mustacchi
Honoraria - Agendia; Celgene; GlaxoSmithKline; Novartis; Pierre Fabre Medicament; Roche
Research Funding - Pierre Fabre Medicament
Daniele Giulio Generali
Research Funding - Pfizer; Roche
Alberto Bottini
Research Funding - Bayer; Roche